Good clinical practice and the use of hypofractionation radiation schedules as weapons to reduce the risk of COVID-19 infections in radiation oncology unit: A mono-institutional experience
暂无分享,去创建一个
L. Giaccherini | A. Botti | C. Iotti | P. Ciammella | D. Ramundo | L. Bardoscia | M. Ruggieri | M. Najafi | S. Cozzi | G. Blandino | M. Manicone | D. Lambertini | A. Rosca | D. S. Solla
[1] L. Beckman,et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. , 2021, The Lancet. Oncology.
[2] V. Borzillo,et al. COVID-19 and radiotherapy: potential new strategies for patients management with hypofractionation and telemedicine. , 2020, European review for medical and pharmacological sciences.
[3] S. Evans,et al. A multi-institutional assessment of COVID-19-related risk in radiation oncology , 2020, Radiotherapy and Oncology.
[4] G. Sanguineti,et al. Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) , 2020, Medical Oncology.
[5] Y. Belkacemi,et al. Radiation Therapy Department Reorganization during the Coronavirus Disease 2019 (COVID-19) Outbreak: Keys to Securing Staff and Patients During the First Weeks of the Crisis and Impact on Radiation Therapy Practice from a Single Institution Experience , 2020, Advances in Radiation Oncology.
[6] Y. Belkacemi,et al. Regional Lymph Node Irradiation in Breast Cancer May Worsen Lung Damage in Coronavirus Disease 2019 Positive Patients , 2020, Advances in Radiation Oncology.
[7] R. Corvò,et al. COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)☆ , 2020, Radiotherapy and Oncology.
[8] A. Kishan,et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 , 2020, Advances in Radiation Oncology.
[9] R. Jagsi,et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic , 2020, Clinical Oncology.
[10] R. Corvò,et al. Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak , 2020, International Journal of Radiation Oncology*Biology*Physics.
[11] C. Simone,et al. Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials , 2019, Oncotarget.
[12] L. Beckman,et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial , 2019, The Lancet.
[13] A. Kishan,et al. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. , 2019, International journal of radiation oncology, biology, physics.
[14] M. Scorsetti,et al. Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction , 2019, Medical Oncology.
[15] K. Hoffman,et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. , 2018, The Journal of urology.
[16] P. Hoskin,et al. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. , 2017, Annals of palliative medicine.
[17] D. Low,et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Annie Gao,et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.
[19] B. Heijmen,et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[20] C. Magnani,et al. Hypofractionated Radiation Therapy for Breast Cancer: Long-Term Results in a Series of 85 Patients , 2016, Tumori.
[21] Anthony Fyles,et al. Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.
[22] J R Yarnold,et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.
[23] K. Wallner,et al. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy , 2006, BJU international.
[24] John E Tomaszewski,et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era , 2002, Cancer.
[25] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[26] E. van Limbergen,et al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial , 2017, JAMA oncology.
[27] R. Stoyanova,et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.